Parameter
| Biomarker | BRAF V600E | Full name | BRAF gene V600E mutation | Molecular Type | Nucleic acid (DNA) |
|---|---|---|---|---|---|
| Molecular Formula | Macromolecule | Molecular Weight | / | Core Functional Dimensions | Diagnosis, classification, and prognosis |
| Disease | Thyroid Cancer | Disease Subtypes | / | ||
| Organ | Thyroid | Test Sample / Technology Platform | Organization (NGS, Sanger sequencing, IHC) | ||
| Pathobiological Mechanisms | Activation of MAPK, and promote the proliferation and tumor | ||||
| Clinical Availability Status | Clinical routine application: 40% 80% PTC detection, is the PTC characteristic mutation; With TERT mutations associated with poor outcome | ||||
| Notes and Dynamics | Combined detection with TERT can optimize risk stratification and guide the selection of targeted therapy | ||||